A detailed history of Ensign Peak Advisors, Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 15,734 shares of MDGL stock, worth $4.94 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,734
Previous 83,373 81.13%
Holding current value
$4.94 Million
Previous $23.4 Million 85.7%
% of portfolio
0.01%
Previous 0.04%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$212.22 - $292.96 $14.4 Million - $19.8 Million
-67,639 Reduced 81.13%
15,734 $3.34 Million
Q2 2024

Aug 13, 2024

SELL
$193.33 - $291.99 $1.71 Million - $2.58 Million
-8,845 Reduced 9.59%
83,373 $23.4 Million
Q1 2024

May 14, 2024

BUY
$171.37 - $283.23 $5.28 Million - $8.73 Million
30,806 Added 50.16%
92,218 $24.6 Million
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $1.25 Million - $2.46 Million
10,365 Added 20.3%
61,412 $14.2 Million
Q3 2023

Nov 13, 2023

BUY
$146.04 - $225.78 $1.44 Million - $2.22 Million
9,850 Added 23.91%
51,047 $7.45 Million
Q2 2023

Aug 14, 2023

BUY
$203.88 - $312.0 $2.74 Million - $4.19 Million
13,421 Added 48.32%
41,197 $9.52 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $6.42 Million - $8.53 Million
27,776 New
27,776 $6.73 Million
Q3 2022

Nov 14, 2022

SELL
$60.57 - $79.51 $515,329 - $676,471
-8,508 Reduced 65.01%
4,580 $298,000
Q2 2022

Aug 12, 2022

BUY
$58.04 - $100.2 $669,085 - $1.16 Million
11,528 Added 738.97%
13,088 $937,000
Q4 2021

Feb 11, 2022

BUY
$72.34 - $95.09 $112,850 - $148,340
1,560 New
1,560 $132,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.37B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.